Bicycle Therapeutics plc (NASDAQ:BCYC) Director Purchases $13,559,062.72 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) Director Bros. Advisors Lp Baker bought 985,397 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was purchased at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the transaction, the director now owns 9,537,643 shares in the company, valued at $131,237,967.68. The trade was a 11.52 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Monday, December 16th, Bros. Advisors Lp Baker acquired 500,000 shares of Bicycle Therapeutics stock. The shares were acquired at an average price of $15.34 per share, with a total value of $7,670,000.00.

Bicycle Therapeutics Price Performance

Shares of BCYC opened at $15.00 on Friday. The firm’s 50 day moving average is $22.06 and its 200-day moving average is $22.56. Bicycle Therapeutics plc has a 12-month low of $12.17 and a 12-month high of $28.67. The stock has a market capitalization of $1.04 billion, a P/E ratio of -4.56 and a beta of 0.86.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. During the same quarter in the previous year, the business posted ($1.26) earnings per share. The firm’s quarterly revenue was down 50.0% compared to the same quarter last year. As a group, equities research analysts forecast that Bicycle Therapeutics plc will post -3.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Armistice Capital LLC increased its stake in Bicycle Therapeutics by 17.9% in the 2nd quarter. Armistice Capital LLC now owns 1,972,000 shares of the company’s stock worth $39,913,000 after purchasing an additional 300,000 shares in the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of Bicycle Therapeutics by 21.5% in the third quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company’s stock worth $41,887,000 after buying an additional 327,089 shares during the period. First Light Asset Management LLC increased its position in shares of Bicycle Therapeutics by 16.1% in the second quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company’s stock worth $28,028,000 after acquiring an additional 191,717 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Bicycle Therapeutics by 1,438.1% during the third quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company’s stock valued at $20,362,000 after acquiring an additional 841,299 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Bicycle Therapeutics by 0.6% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock valued at $17,975,000 after acquiring an additional 4,976 shares in the last quarter. 86.15% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on BCYC shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. B. Riley cut their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. HC Wainwright decreased their target price on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a research report on Monday. Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Finally, JMP Securities decreased their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $35.25.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.